Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria C Bolling

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
The British Journal of Dermatology|May 3, 2022
The importance of accurate epidemiological data of epidermolysis bullosaRosalie Baardman, Maria C Bolling
The Journal of Investigative Dermatology|December 24, 2018
KLHL24: Beyond Skin FragilityMaria C Bolling, Marcel F Jonkman
Experimental Dermatology|June 30, 2009
Skin and heart: une liaison dangereuseMaria C Bolling, Marcel F Jonkman
Experimental Dermatology|April 16, 2025
Understanding Genotype-Phenotype Correlations of Desmoplakin Splice Site VariantsMaria C Bolling, Mathilde C S C Vermeer
JAMA Dermatology|March 2, 2022
Understanding the Potential Promise and Pitfalls of Intravenous Gentamicin as a Therapy for Epidermolysis BullosaMaria C Bolling, Cristina Has, Anna L Bruckner
Dermatologic Clinics|December 1, 2009
Lethal acantholytic epidermolysis bullosaJohn A McGrath, Maria C Bolling, Marcel F Jonkman
Clinical Case Reports|July 31, 2025
Neonatal Epidermolytic Ichthyosis Caused by a KRT10 Mutation (c.467G>A, p.Arg156His): A Case ReportElke Smits, Gunnar Naulaers, Maria C Bolling, et al.
Biomedicines|September 23, 2022
Revertant Mosaicism in Genodermatoses: Natural Gene Therapy Right before Your EyesPeter C van den Akker, Maria C Bolling, Anna M G Pasmooij
JAAD International|March 7, 2022
The positive impact of rituximab on the quality of life and mental health in patients with pemphigusHanan Rashid, Mila Poelhekken, Joost M Meijer, et al.
The Journal of Clinical Investigation|May 4, 2007
Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3Anna M G Pasmooij, Hendri H Pas, Maria C Bolling, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
The British Journal of Dermatology|May 3, 2022
The importance of accurate epidemiological data of epidermolysis bullosaRosalie Baardman, Maria C Bolling
The Journal of Investigative Dermatology|December 24, 2018
KLHL24: Beyond Skin FragilityMaria C Bolling, Marcel F Jonkman
Experimental Dermatology|June 30, 2009
Skin and heart: une liaison dangereuseMaria C Bolling, Marcel F Jonkman
Experimental Dermatology|April 16, 2025
Understanding Genotype-Phenotype Correlations of Desmoplakin Splice Site VariantsMaria C Bolling, Mathilde C S C Vermeer
JAMA Dermatology|March 2, 2022
Understanding the Potential Promise and Pitfalls of Intravenous Gentamicin as a Therapy for Epidermolysis BullosaMaria C Bolling, Cristina Has, Anna L Bruckner
Dermatologic Clinics|December 1, 2009
Lethal acantholytic epidermolysis bullosaJohn A McGrath, Maria C Bolling, Marcel F Jonkman
Clinical Case Reports|July 31, 2025
Neonatal Epidermolytic Ichthyosis Caused by a KRT10 Mutation (c.467G>A, p.Arg156His): A Case ReportElke Smits, Gunnar Naulaers, Maria C Bolling, et al.
Biomedicines|September 23, 2022
Revertant Mosaicism in Genodermatoses: Natural Gene Therapy Right before Your EyesPeter C van den Akker, Maria C Bolling, Anna M G Pasmooij
JAAD International|March 7, 2022
The positive impact of rituximab on the quality of life and mental health in patients with pemphigusHanan Rashid, Mila Poelhekken, Joost M Meijer, et al.
The Journal of Clinical Investigation|May 4, 2007
Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3Anna M G Pasmooij, Hendri H Pas, Maria C Bolling, et al.
Pageof 6